Christopher W. Ryan

机构：West Virginia University, Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa, Oregon Health & Science University, West Virginia University Hospitals, Fred Hutch Cancer Center, OHSU Knight Cancer Institute · ORCID：0000-0002-4259-1123

发表论文 287 篇 · 总被引 9899 次 · h-index 47

代表论文

• Randomized, Double-Blind Phase III Study of Pazopanib Versus Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease After Metastasectomy: ECOG-ACRIN E2810 (2024 · Journal of Clinical Oncology · 被引 20)
• SWOG 1609 cohort 48: anti–CTLA‐4 and anti–PD‐1 for advanced gallbladder cancer (2024 · Cancer · 被引 18)
• Long-term efficacy and safety of pexidartinib in patients with tenosynovial giant cell tumor: final results of the ENLIVEN study (2025 · The Oncologist · 被引 14)
• Phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: adrenocortical carcinoma cohort (2024 · Journal for ImmunoTherapy of Cancer · 被引 13)
• SWOG/NCI Phase II Dual Anti–CTLA-4/PD-1 Blockade in Rare Tumors: Nonepithelial Ovarian Cancer (2024 · Clinical Cancer Research · 被引 12)
• A phase 4, multicenter, global clinical study to evaluate discontinuation and rechallenge of pexidartinib in patients with tenosynovial giant cell tumor previously treated with pexidartinib (2024 · Cancer · 被引 11)